A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
This 2 arm study will assess the long term safety and efficacy of RO4607381 in patients with
coronary heart disease or a coronary heart disease (CHD) risk equivalent who have completed
study NC19453. Patients eligible to participate in the extension study will continue on the
treatment they were originally assigned to ie RO4607381 (900mg po) or placebo daily, with
concomitant daily atorvastatin (10 to 80mg po). The anticipated time on study treatment is 6
months post study NC19453, and the target sample size is approximately 100 individuals.